UPDATE: MLV & Co Raises PT On Keryx Biopharmaceuticals On Additional Auryxia Growth Potential
January 07, 2015 at 09:19 AM EST
In a report published Wednesday, MLV & Co analyst George B. Zavoico reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX), ...